BIOCARE Lifesciences Inc., the exclusive importer and distributor of Sepsivac (Mycobacterium w) in the Philippines, received on Sept. 15, 2021 its Compassionate Special Permit after the Food and Drugs Administration approved the drug for Covid-19 treatment. Sepsivac — a first-in-the-world innovation for sepsis management — was developed under the New Millennium India Technology Initiative program of Council of Scientific and Industrial Research and is manufactured by Cadila Pharmaceuticals Ltd., Ahmedabad.

“Being able to offer Sepsivac to coronavirus patients and medical care partners is an exciting step forward for Biocare, and the partnership with Cadila Pharmaceuticals Ltd. Is one that we are extremely proud of,” said Dileep Tiwari, managing director at Biocare Lifesciences Inc.

“With the launch of Sepsivac, we’re currently ready to satisfy our objective and mission in acquiring quality and affordable medicine in this time of pandemic. Having Sepsivac is a great addition to the company’s product portfolio for Covid-19. This is after we launched remdesivir and favipiravir last year and tocilizumab in April 2021,” Tiwari said.

poster

Sepsivac contains heat-killed Mycobacterium W (Mw), an immunomodulator. The immunomodulator effect was found to reduce the mortality rate of critically ill patients suffering from gram-negative sepsis by more than half.

WHO tests 3 drugs for Covid; deaths hit 4.31M “The efficacy of Sepsivac, originally used for the treatment of leprosy, was repurposed for use against Covid-19,” according to Ronald Palacio, business unit head of Biocare Lifesciences Inc.

Palacio added, “Based on the clinical studies conducted for moderate to severe Covid-19 patients, Sepsivac effectively saves more lives in sepsis. Randomized trials in sepsis patients showed 11-percent absolute reduction and 55.5-percent relative reduction in mortality. Additionally, hospitalized Covid-19 patients reduce the days on ventilator, ICU stay, hospital stay, incidences of secondary infection and days on vasopressor, and reduce the SOFA (Sequential Organ Failture Assessment) score.”

Resource: